Imidazole p97 Modulators for Neurodegenerative Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors and modulators of the p97 protein to treat cancer and neurodegenerative disorders caused by proteostatic malfunction, with a requirement for compounds that are more efficacious and have fewer side effects than existing p97 inhibition mechanisms.
Innovation Solution
The development of specific compounds, represented by Formulae (I), (Ia), (Ib), (Ic), (IIa), (IIb), and (III), which are designed to modulate or inhibit p97 activity, including imidazoles with p97 inhibitory or modulatory activity, to treat conditions such as inclusion body myopathy, Paget's disease of the bone, frontotemporal dementia, and amyotrophic lateral sclerosis, as well as antibacterial and antiviral infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing p97 inhibition mechanisms are used, then p97 activity is inhibited, but side effects increase and efficacy is reduced
Solution Approach 1:
The patent modifies the chemical structure of p97 inhibitors by changing molecular parameters such as substituting specific hydrogen atoms with fluorine atoms (e.g., in the imidazole ring system), adjusting substituent groups on aromatic rings, and modifying linker chains. These parameter changes in the molecular structure lead to improved binding affinity and selectivity for p97, thereby enhancing therapeutic efficacy while reducing off-target effects and side effects.
Solution Approach 2:
The patent introduces specific local modifications to the inhibitor molecules, such as placing electron-withdrawing groups at particular positions on the aromatic rings, adding specific substituent groups at defined locations, and modifying specific regions of the molecular structure. These localized quality changes optimize the interaction between the inhibitor and the p97 active site, improving both efficacy and selectivity while minimizing harmful interactions with other cellular targets.
2Reliability
If p97 activity is strongly inhibited, then therapeutic benefit increases, but cellular proteostasis disruption worsens
Solution Approach 1:
The patent designs inhibitors that achieve partial inhibition of p97 activity rather than complete blockade. By optimizing the potency and selectivity of the inhibitors, the patent enables sufficient inhibition to achieve therapeutic benefit while avoiding excessive inhibition that would cause severe proteostasis disruption. This is accomplished through precise molecular design that targets specific disease-relevant p97 functions while preserving essential cellular processes.
3Adaptability or versatility
If broad-spectrum p97 inhibitors are developed, then more disease conditions are treated, but specificity and reduced side effects are compromised
Solution Approach 1:
The patent develops a series of p97 inhibitors with a core imidazole-based structure that can be systematically modified to target different disease conditions. The universal imidazole core provides consistent p97 binding capability across multiple applications, while variable substituent groups allow optimization for specific disease indications such as cancer, neurodegenerative disorders, and infectious diseases. This multi-functional design enables broad disease applicability while maintaining high specificity through structure-activity relationship optimization.
Data Source
AI summary
The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.